CoChat

Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Cagrilintide and semaglutide have each been shown to induce weight loss as monotherapies. Data are needed on the coadministration of cagrilintide and semaglutide (called CagriSema) for weight management in adults with type 2 diabetes, including those in a subgroup who are undergoing continuous glucose monitoring. METHODS: In this phase 3a, double-blind, randomized, placebo-controlled trial conducted in 12 countries, we assigned adults with a body-mass index of 27 or more, a glycated hemoglobin level of 7 to 10%, and type 2 diabetes in a 3:1 ratio to receive once-weekly cagrilintide-semaglutide (2.4 mg each) or placebo, along with lifestyle intervention, for 68 weeks. The two primary end points were the percent change in body weight and the percentage of patients with a weight reduction of at least 5%. Additional end points were changes in glycemic measures and safety assessments. Effect estimates were calculated with the use of the treatment-policy estimand (consistent with the intention-to-treat principle). RESULTS: A total of 1206 patients underwent randomization to either the cagrilintide-semaglutide group (904 patients) or the placebo group (302 patients). The estimated mean change in body weight from baseline to week 68 was -13.7% in the cagrilintide-semaglutide group and -3.4% in the placebo group (estimated difference, -10.4 percentage points; 95% confidence interval, -11.2 to -9.5; P<0.001). More patients in the cagrilintide-semaglutide group than in the placebo group had a weight reduction of 5% or more (P<0.001); the same was true of reductions of at least 10%, 15%, and 20% (P<0.001 for the last comparison). The percentage of patients who had a glycated hemoglobin level of 6.5% or less was 73.5% in the cagrilintide-semaglutide group and 15.9% in the placebo group. Gastrointestinal adverse events were reported by 72.5% of the patients in the cagrilintide-semaglutide group and 34.4% in the placebo group, most of which were transient and mild or moderate in severity. CONCLUSIONS: Once-weekly cagrilintide-semaglutide (at a dose of 2.4 mg each) resulted in a significantly lower body weight than placebo in adults with obesity and type 2 diabetes. (Funded by Novo Nordisk; REDEFINE 2 ClinicalTrials.gov number, NCT05394519.).

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmoa2502082

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 28 references

Cited by

See all 143

Metadata

Authors
Davies, M. J., Bajaj, H. S., Broholm, C., Eliasen, A., Garvey, W. T., le Roux, C. W., Lingvay, I., Lyndgaard, C. B., Rosenstock, J., & Pedersen, S. D.
Affiliations
  • University of Leicester (GB)
  • Endocrine and Metabolic Research, LMC Healthcare, Brampton, ON, Canada
  • Novo Nordisk (Denmark) (DK)
  • University of Alabama at Birmingham (US)
  • Diabetes Complications Research Centre, University College Dublin School of Medicine, Dublin
  • The University of Texas Southwestern Medical Center (US)
  • Velocity Clinical Research at Medical City, Dallas
  • C-ENDO Diabetes and Endocrinology Clinic Calgary, Calgary, AB, Canada
Venue
New England Journal of Medicine
Published
2025-08-14
Volume
393
Issue
7
Pages
648-659
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4411522182
Cited by
143
References
28
Citations by year
2026: 105 · 2025: 38
FWCI
96.79
Type
journal article
Language
en
Open access
closed
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
Novo Nordisk A/S
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
cagrilintide, semaglutide, type 2 diabetes, obesity, overweight, weight loss, combination therapy, continuous glucose monitoring, HbA1c, gastrointestinal adverse effects, drug safety, lifestyle intervention, treatment policy estimand, weight management, drug repurposing, GLP-1 receptor agonists
MeSH terms
Continuous Glucose Monitoring, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Combinations, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Life Style, Male, Middle Aged, Obesity, Weight Loss, Body Mass Index, Treatment Outcome, Overweight, Glucagon-Like Peptide 1, Intention to Treat Analysis, Islet Amyloid Polypeptide

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. https://app.cochat.ai/papers/10.1056/nejmoa2502082
The paper
Davies, M. J., Bajaj, H. S., Broholm, C., Eliasen, A., Garvey, W. T., le Roux, C. W., Lingvay, I., Lyndgaard, C. B., Rosenstock, J., & Pedersen, S. D. (2025). Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2502082

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.